(NP (NP (NN Induction)) (PP (IN of) (NP (JJ vascular) (NN cell) (NN adhesion) (NN molecule-1))) (PP (IN by) (NP (JJ low-density) (NN lipoprotein))) (. .))
(S (NP-SBJ (NP (JJ Low-density) (NN lipoprotein)) (PRN (-LRB- -LRB-) (NP (NN LDL)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ well-established) (NN risk) (NN factor)) (PP (IN for) (NP (NN atherosclerosis))))) (. .))
(S (SBAR-TMP (WHADVP-49 (WRB When)) (S (NP-SBJ-50 (JJ endothelial) (NNS cells)) (VP (VBP are) (VP (VBN incubated) (NP (-NONE- *-50)) (PP (IN with) (NP (DT this) (NN lipoprotein))) (PP (IN in) (NP (JJ pathophysiologic) (NNS amounts))) (ADVP (-NONE- *T*-49)))))) (, ,) (NP-SBJ-51 (DT the) (NNS cells)) (VP (VBP are) (VP (VBN activated) (NP (-NONE- *-51)))) (. .))
(SINV (PP-PRD-TPC-103 (IN Among) (NP (NP (DT the) (VBN documented) (JJ cellular) (NNS responses)) (PP (TO to) (NP (NN LDL))))) (VP (VBZ is) (PP-PRD (-NONE- *T*-103))) (NP-SBJ (NP (VBN increased) (NN recruitment)) (PP (IN of) (NP (NP (NNS monocytes)) (, ,) (SBAR (WHNP-52 (WDT which)) (S (NP-SBJ-53 (-NONE- *T*-52)) (VP (VBP are) (VP (VBN believed) (S (NP-SBJ-104 (-NONE- *-53)) (VP (TO to) (VP (VB play) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (S (NP-SBJ (-NONE- *-104)) (VP (VBG promoting) (NP (JJ intimal) (NN plaque) (NN formation))))))))))))))) (. .))
(S (NP-SBJ (NP (DT The) (NNS findings)) (VP (VBN presented) (NP (-NONE- *)) (ADVP (RB here)))) (VP (VB link) (NP (NP (DT an) (JJ atheogenic) (NN lipoprotein)) (, ,) (NP (NN LDL)) (, ,)) (PP (IN with) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (DT an) (NN adhesion) (NN molecule)) (ADJP (JJ important) (PP (IN in) (NP (NN atherogenesis))))))))))
(S (NP-SBJ (JJ Human) (NN LDL)) (VP (VBZ induces) (NP (NP (DT the) (JJ vascular) (NN cell) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN VCAM-1)) (-RRB- -RRB-))) (ADVP (RB transcriptionally)) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN mRNA) (NNS levels))))) (PP (IN through) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN VCAM) (NN promoter)))))) (. .))
(S (NP-SBJ-54 (DT This) (NN effect)) (VP (VBZ is) (VP (VBN blocked) (NP (-NONE- *-54)) (PP (IN by) (NP-LGS (JJ anti-VCAM) (NNS antibodies))))) (. .))
(S (PP-TMP (IN After) (NP (NP (DT a) (JJ 2-day) (NN incubation)) (PP (IN in) (NP (NN LDL))))) (, ,) (NP-SBJ (NP (DT the) (NN binding)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B)) (, ,) (SBAR (WHNP-55 (WDT which)) (S (NP-SBJ-56 (-NONE- *T*-55)) (VP (VBZ is) (VP (VBN believed) (S (NP-SBJ (-NONE- *-56)) (VP (TO to) (VP (VB be) (NP-PRD (NP (DT a) (JJ key) (JJ oxidative-stress) (NN sensor)) (PP (IN for) (NP (NN VCAM) (NN regulation))))))))))) (, ,)))) (VP (VBZ remains) (PP (IN at) (NP (JJ basal) (NN level)))) (. .))
(S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-57 (NP (DT the) (NN binding) (NNS activities)) (PP (IN of) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN GATA))))) (, ,) (PP (IN on) (NP (DT the) (JJ other) (NN hand))) (, ,) (VP (VBP are) (VP (VBN increased) (NP (-NONE- *-57)) (PP (IN by) (NP-LGS (NN LDL))))) (. .))
(S (ADVP (RB Thus)) (, ,) (NP-SBJ-58 (NP (DT a) (NN component)) (PP (IN of) (NP (NP (JJ LDL-enhanced) (JJ endothelial) (NN recruitment)) (PP (IN of) (NP (NNS monocytes)))))) (VP (VBZ is) (VP (VBN attributed) (NP (-NONE- *-58)) (PP (TO to) (NP (NP (JJ VCAM-1) (NN expression)) (, ,) (SBAR (WHNP-59 (WDT which)) (S (NP-SBJ-60 (-NONE- *T*-59)) (VP (VBZ appears) (S (NP-SBJ-61 (-NONE- *-60)) (VP (TO to) (VP (VB be) (VP (VBN mediated) (NP (-NONE- *-61)) (PP (IN through) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN GATA))))))))))))))) (. .))
(S (NP-SBJ (DT These) (NNS data)) (VP (VBP identify) (NP (NN LDL)) (PP (IN as) (NP (NP (DT a) (NN VCAM-inducer)) (ADJP (ADVP (RB possibly)) (JJ distinct) (PP (IN from) (NP-COOD (NP (NNS cytokines)) (CC and) (NP (NN endotoxin)))))))) (. .))
